{"id":46360,"date":"2022-07-20T12:01:58","date_gmt":"2022-07-20T10:01:58","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/"},"modified":"2022-07-20T12:01:58","modified_gmt":"2022-07-20T10:01:58","slug":"camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/","title":{"rendered":"CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic"},"content":{"rendered":"
\n

\n– Proceeds to Support Clinical Development of Lead CNS & Liver Programs; <\/i>IND for Dravet Syndrome is Anticipated by Mid-2023<\/i>\n<\/p>\n

\n– New Capital Will Also Fuel Expansion of CAMP4\u2019s regRNA Actuating Platform\u2122, Harnessing the Power of Regulatory RNA to Upregulate Gene Expression<\/i>\n<\/p>\n

\n– Funding Round Led by Enavate Sciences, a Portfolio Company of Patient Square Capital; <\/i>Enavate CEO Jim Boylan Joins CAMP4\u2019s Board of Directors<\/i>\n<\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy protein expression, today announced the closing of a $100 million Series B round to advance the company\u2019s lead regRNA programs and accelerate the expansion of the company\u2019s regRNA Actuating Platform. Enavate Sciences, a portfolio company created by Patient Square Capital, led the round. Additional investors in the Series B financing include a large national managed care organization and the Gaingels, an LGBTQIA+\/Allies investment syndicate supporting diversity in venture capital, along with other unnamed investors. Existing investors 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz, The Kraft Group, and others also joined the round.\n<\/p>\n

<\/a><\/p>\n

\nCAMP4\u2019s approach uniquely targets regulatory RNAs (\u201cregRNAs\u201d), considered to be part of the \u201cDark Side of the Genome,\u201d the 98% of our genome that does not encode proteins. Through breakthroughs in molecular biology, it is now known that regRNAs control the expression of nearby protein-encoding genes. CAMP4\u2019s RNA Actuating Platform (RAP\u2122) maps regRNAs associated with every protein-coding gene in any cell type, and its programmable antisense oligonucleotide (ASO) therapeutics target the controlling regRNAs to upregulate gene expression to treat disease. This approach is applicable to a range of genetic diseases in which tunable increases in gene output can lead to meaningful therapeutic outcomes.\n<\/p>\n

\n\u201cWe have made massive advancements in the field of regRNAs and our ability to target these \u2018dark side\u2019 molecules to elegantly control the expression of genes for therapeutic purposes,\u201d says Josh Mandel-Brehm, CEO of CAMP4. \u201cFor any disease-associated gene, we can identify the regRNA controlling it with our proprietary RAP platform and then rapidly develop an antisense oligonucleotide to precisely increase gene output. This is an efficient, repeatable approach for more than a thousand known genetic diseases in which a patient is under-expressing a key protein. The incredible support we\u2019ve received in our Series B round is a testament to the promise and vast potential of our transformative regulatory RNA platform and the impact it could have for patients with genetic diseases.\u201d\n<\/p>\n

\nThe company expects to enter the clinic with its lead candidate to treat Dravet syndrome by mid-2023. The financing round will further support the advancement of CAMP4\u2019s drug candidates, including progressing its urea cycle disorder program into the clinic and continuing to build an expansive pipeline of RNA actuators. While the company is initially focusing on treating diseases of the central nervous system and liver, its platform has the potential to address a broad range of genetic indications across multiple tissues, with a focus on haploinsufficient diseases.\n<\/p>\n

\n\u201cWe see immense opportunity and value in CAMP4\u2019s truly unique approach of upregulating gene expression using antisense oligonucleotides, a proven modality for regulating gene expression,\u201d says James Boylan, Chief Executive Officer of Enavate Sciences. \u201cGroundbreaking insights into regRNAs, powered by internally-derived machine learning algorithms, and our ability to drug targets with ASOs have merged together in CAMP4\u2019s proprietary platform to advance an entirely new class of medicines. We\u2019re excited to lead this financing and partner with CAMP4 to help realize the full potential of RNA actuators for patients with genetic diseases.\u201d\n<\/p>\n

\nIn conjunction with the financing, Mr. Boylan will join CAMP4\u2019s Board of Directors.\n<\/p>\n

\nAbout CAMP4 Therapeutics<\/b>\n<\/p>\n

\nAt CAMP4, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our RNA Actuating Platform\u2019s proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of diseases affecting millions of patients. Learn more about us at www.CAMP4tx.com<\/a> and follow us @CAMP4tx<\/a>.\n<\/p>\n

\nAbout Enavate Sciences<\/b>\n<\/p>\n

\nEnavate Sciences is a platform created by Patient Square Capital dedicated to supporting therapeutic companies advancing medicines and enabling technologies with transformative potential to address patient need. Through the application of capital support and operational experience, Enavate strives to enable and empower a diverse portfolio of therapeutics companies to accelerate innovation. To learn more about Enavate, please visit www.enavatesciences.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKristie Wallis
\n
Scient PR
\n
kristie@scientpr.com<\/a>
646-320-3845\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Proceeds to Support Clinical Development of Lead CNS & Liver Programs; IND for Dravet Syndrome is Anticipated by Mid-2023 – New Capital Will Also Fuel Expansion of CAMP4\u2019s regRNA Actuating Platform\u2122, Harnessing the Power of Regulatory RNA to Upregulate Gene Expression – Funding Round Led by Enavate Sciences, a Portfolio Company of Patient Square … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46360","6":"format-standard","7":"category-industry"},"yoast_head":"\nCAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Proceeds to Support Clinical Development of Lead CNS & Liver Programs; IND for Dravet Syndrome is Anticipated by Mid-2023 – New Capital Will Also Fuel Expansion of CAMP4\u2019s regRNA Actuating Platform\u2122, Harnessing the Power of Regulatory RNA to Upregulate Gene Expression – Funding Round Led by Enavate Sciences, a Portfolio Company of Patient Square ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-20T10:01:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220720005150\/en\/1518360\/21\/CMP4_21_logo_full_color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic\",\"datePublished\":\"2022-07-20T10:01:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\\\/\"},\"wordCount\":781,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005150\\\/en\\\/1518360\\\/21\\\/CMP4_21_logo_full_color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\\\/\",\"name\":\"CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005150\\\/en\\\/1518360\\\/21\\\/CMP4_21_logo_full_color.jpg\",\"datePublished\":\"2022-07-20T10:01:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005150\\\/en\\\/1518360\\\/21\\\/CMP4_21_logo_full_color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005150\\\/en\\\/1518360\\\/21\\\/CMP4_21_logo_full_color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/","og_locale":"en_US","og_type":"article","og_title":"CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic - Pharma Trend","og_description":"– Proceeds to Support Clinical Development of Lead CNS & Liver Programs; IND for Dravet Syndrome is Anticipated by Mid-2023 – New Capital Will Also Fuel Expansion of CAMP4\u2019s regRNA Actuating Platform\u2122, Harnessing the Power of Regulatory RNA to Upregulate Gene Expression – Funding Round Led by Enavate Sciences, a Portfolio Company of Patient Square ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-20T10:01:58+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220720005150\/en\/1518360\/21\/CMP4_21_logo_full_color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic","datePublished":"2022-07-20T10:01:58+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/"},"wordCount":781,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220720005150\/en\/1518360\/21\/CMP4_21_logo_full_color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/","url":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/","name":"CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220720005150\/en\/1518360\/21\/CMP4_21_logo_full_color.jpg","datePublished":"2022-07-20T10:01:58+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220720005150\/en\/1518360\/21\/CMP4_21_logo_full_color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220720005150\/en\/1518360\/21\/CMP4_21_logo_full_color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46360"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46360\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}